AU Patent

AU2020231506A1 — Methods for the treatment of perimenopause and menopause

Assigned to Praxis Precision Medicines Inc · Expires 2021-09-30 · 5y expired

What this patent protects

The invention relates to methods of treating the symptoms of perimenopause or menopause using positive allosteric modulators γ-aminobutyric acid type A (GABA-A PAMs) receptor, including 3α-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5α-pregnan-20-one and salts thereof.

USPTO Abstract

The invention relates to methods of treating the symptoms of perimenopause or menopause using positive allosteric modulators γ-aminobutyric acid type A (GABA-A PAMs) receptor, including 3α-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5α-pregnan-20-one and salts thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020231506A1
Jurisdiction
AU
Classification
—
Expires
2021-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Praxis Precision Medicines Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.